Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is overpriced on P/FCF.
Target Price
The average target price of AXSM is 224 and suggests 23% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell